The Zhitong Finance App learned that Novartis Pharmaceuticals (NVS.US) ushered in a “double day of ice and fire” in the field of neurology and autoimmunity: the company urgently suspended eight clinical trials of CAR-T therapy due to the deaths of three patients; however, its multiple sclerosis (MS) oral drug remibrutinib achieved positive results in later clinical trials.

The Zhitong Finance App learned that Novartis Pharmaceuticals (NVS.US) ushered in a “double day of ice and fire” in the field of neurology and autoimmunity: the company urgently suspended eight clinical trials of CAR-T therapy due to the deaths of three patients; however, its multiple sclerosis (MS) oral drug remibrutinib achieved positive results in later clinical trials.